Company Analysis
Sign in

Lite Strategy, Inc. (LITS)

Nasdaq: LITS · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2003
Full chart Alerts Compare
Grade3.5
◀ Past 3.5● Present 2.5▶ Future 4.3
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

39 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Lite Strategy, Inc.’s names, not what it holds today.

Patents granted
39
39 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 2 in 2024 and 2 in 2023
Applications published
59
1 of them in 2025
Names they are printed under
3
a former name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals9
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
MEI Pharma, Inc. a former name
named as the applicant on its applications, in US
0 granted
43 published
MEI PHARMA, INC. a former name
US, as the owner printed on each patent
33 granted
9 published
Marshall Edwards, Inc. a former name
US, as the owner printed on each patent
6 granted
7 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 23, 202512,421,216Voruciclib polymorphs and methods of making and using thereofOrganic fine chemistryMEI PHARMA, INC.
Dec 10, 202412,161,644Combination therapyPharmaceuticalsMEI PHARMA, INC.
Aug 13, 202412,059,422(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseasesPharmaceuticalsMEI PHARMA, INC.
Aug 15, 202311,723,893Isoflavonoid compositions and methods for the treatment of cancerPharmaceuticalsMEI PHARMA, INC.
Feb 21, 202311,583,514Isoflavonoid compounds and methods for the treatment of cancerPharmaceuticalsMEI PHARMA, INC.
Aug 2, 202211,400,097(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseasesPharmaceuticalsMEI PHARMA, INC.
Jun 7, 202211,351,176Combination therapyPharmaceuticalsMEI PHARMA, INC.
Apr 19, 202211,304,953Combination therapyPharmaceuticalsMEI PHARMA, INC.
Apr 20, 202110,980,774Combination therapiesPharmaceuticalsMEI PHARMA, INC.
Apr 13, 202110,973,799Isoflavonoid compositions and methods for the treatment of cancerPharmaceuticalsMEI PHARMA, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jun 5, 20252025/0177409COMBINATION THERAPY OF PI3K INHIBITOR AND PD-1 INHIBITORPharmaceuticalsMEI Pharma, Inc.
Jun 20, 20242024/0197680VORUCICLIB DOSING REGIMENS AND METHODS OF TREATMENT INCLUDING THE SAMEPharmaceuticalsMEI PHARMA, INC.
May 23, 20242024/0165073ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERPharmaceuticalsMEI Pharma, Inc. · patent 12,318,364 granted from it
Jan 18, 20242024/0016781TREATMENT OF KRAS MUTANT CANCERSPharmaceuticalsMEI PHARMA, INC.
Nov 23, 20232023/0372287ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCERPharmaceuticalsMEI Pharma, Inc. · patent 12,329,739 granted from it
Jul 27, 20232023/0233519COMBINATION THERAPIESPharmaceuticalsMEI Pharma, Inc.
Jun 1, 20232023/0167096VORUCICLIB POLYMORPHS AND METHODS OF MAKING AND USING THEREOFOrganic fine chemistryMEI PHARMA, INC. · patent 12,421,216 granted from it
May 11, 20232023/0145478ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCERPharmaceuticalsMEI Pharma, Inc.
Apr 27, 20232023/0129089PREPARATION OF A 1,3,5-TRIAZINYL BENZIMIDAZOLEOrganic fine chemistryMEI Pharma, Inc.
Oct 13, 20222022/0323449(ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASESPharmaceuticalsMEI Pharma, Inc. · patent 12,059,422 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 4.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton LITS · research, not advice